Skip to main content

Table 3 Patients with dose-limiting toxicity events

From: A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

huKS-IL2 dosing cohort, mg/m2 Patient age, years DLT AE gradea Day started (cycle) Duration, days DLT outcome
2.0 63 Hypoxia 3 2 (1) 2 Recovered
3.0 59 Dyspnea 3 3 (1) 25 Recovered
Bronchospasm 3 4 (1) 2 Recovered
GGT increased 3 4 (1) 19 Recovered
4.0 55 Thrombocytopenia 4 8 (1) 3 Recovered
Neutropenia 3 8 (1) 3 Recovered
63 Anemiab 3 5 (1) 2 Recovered
  1. a National Cancer Institute Common Terminology Criteria for Adverse Events grade.
  2. b Patient entered study with anemia, but was hospitalized after dosing for a blood transfusion.
  3. DLT, dose-limiting toxicity; GGT, gamma-glutamyltransferase; huKS-IL2, humanized KS-interleukin-2.